Viking Therapeutics (VKTX) Company Report

VKTX's oral VK2735 (GLP-1/GIP dual agonist for obesity) successfully completed its VENTURE Phase 2 study, achieving its primary endpoint with up to 14.7% mean weight loss after 13 weeks and demonstrating promising tolerability. An End of Phase 2 meeting with the FDA is scheduled for later this year.
The injectable VK2735 formulation is progressing into Phase 3, with two VANQUISH studies initiated in 2Q25. Enrollment for VANQUISH 1 is complete, and VANQUISH 2 enrollment is expected to conclude in 1Q26.
Other pipeline developments include successful Phase 2b data for VK2809 (MASH) reported in 2Q24 and successful Phase 1b data for VK0214 (X-ALD) reported in 4Q24. An Investigational New Drug (IND) application for an Amylin agonist for obesity is planned for 1Q26.

2 days ago

Presentation

Viking Therapeutics Provides Update on VK2735 Obesity Programs and Financial Position

VKTX

New Projects/Investments

Guidance Update

Viking Therapeutics is advancing VK2735, a GLP-1 GIP dual agonist, with its subcutaneous formulation in Phase III for obesity and an oral formulation having completed a Phase II study.
Enrollment for the VANQUISH I Phase III study has been completed, and VANQUISH II is expected to complete enrollment in Q1 2026.
The oral formulation of VK2735 demonstrated up to 12.2% body weight reduction after 13 weeks in its Phase II study, with an end-of-Phase II meeting with the FDA planned by year-end 2025.
The company reported over $700 million in cash at the end of the third quarter, which is expected to fund operations through the VANQUISH Phase III data readouts.

2 days ago

Transcript

Viking Therapeutics Updates on VK2735 Obesity Programs and Financials

VKTX

Product Launch

New Projects/Investments

Viking Therapeutics' lead drug, VK2735, a GLP-1, GIP dual agonist for obesity, is progressing with both subcutaneous and oral formulations.
The subcutaneous VK2735 is in Phase III (VANQUISH program), with VANQUISH-1 (obesity) having completed enrollment and VANQUISH-2 (obesity and type 2 diabetes) expected to complete enrollment in Q1 2026.
The oral formulation of VK2735 recently completed a Phase II study, demonstrating up to 12.2% body weight reduction after 13 weeks and excellent tolerability; the company plans an end-of-Phase II meeting with the FDA by the end of 2025.
The company reported over $700 million in cash at the end of Q3 2025, which is expected to fund operations through the VANQUISH Phase III data readouts.

2 days ago

Transcript

Viking Therapeutics Provides Update on VK2735 Clinical Programs and Financial Position

VKTX

New Projects/Investments

Guidance Update

Viking Therapeutics is focused on metabolic and endocrine disorders, with its lead program, VK2735, a GLP-1, GIP dual agonist for obesity, currently in Phase 3 trials for the subcutaneous formulation.
Enrollment for the Vanquish One Phase 3 study has been completed, and enrollment for the Vanquish Two study is expected to be completed in Q1 2026.
The oral formulation of VK2735 recently completed a Phase 2 study, demonstrating up to 12.2% body weight reduction after 13 weeks. The company plans an end-of-Phase 2 meeting with the FDA by the end of 2025 to determine next steps.
Viking also has an amylin agonist approaching the clinic, with an Investigational New Drug (IND) filing expected in Q1 2026.
The company reported over $700 million in cash at the end of Q3, which is expected to fund operations through the Vanquish Phase 3 data readouts.

2 days ago

Transcript

Viking Therapeutics Completes Enrollment in Phase 3 VANQUISH-1 Trial

VKTX

Product Launch

New Projects/Investments

Viking Therapeutics (VKTX) announced the completion of patient enrollment in its Phase 3 VANQUISH-1 clinical trial for subcutaneous VK2735, a dual GLP-1/GIP receptor agonist for obesity.
The trial enrolled approximately 4,650 adults with obesity or who are overweight, completing ahead of schedule and above target size.
The primary endpoint of the 78-week trial is the percent change in body weight from baseline.
This follows positive results from the 2024 Phase 2 VENTURE study, where VK2735 demonstrated statistically significant mean body weight reductions of up to 14.7% after 13 weeks.
The company expects to complete enrollment in its related Phase 3 VANQUISH-2 study in the first quarter of 2026.

2 days ago

Press Release

Viking Therapeutics Highlights Positive VK2735 Cardiometabolic Data at ObesityWeek 2025

VKTX

Viking Therapeutics announced new clinical data from its VK2735 obesity program at ObesityWeek® 2025, demonstrating improved cardiometabolic parameters.
An exploratory analysis of the Phase 2 VENTURE trial showed that 78% of VK2735-treated prediabetic patients achieved normal glycemic status by Week 13, compared to 29% for placebo (p=0.0008).
Additionally, 68% of VK2735-treated patients with metabolic syndrome (MetS) at baseline no longer met MetS criteria at Week 13, versus 38% for placebo (p=0.02).
These findings complement previously reported significant mean body weight reductions of up to 14.7% and up to 88% of patients achieving ≥10% weight loss, highlighting VK2735's potential for comprehensive cardiometabolic health improvement.
VK2735, a dual GLP-1/GIP receptor agonist, is currently being evaluated in a Phase 3 obesity program for its subcutaneous formulation.

Nov 6, 2025, 12:05 PM

Press Release

Viking Therapeutics Reports Q3 2025 Financial Results and Provides Corporate Update

VKTX

Earnings

New Projects/Investments

Viking Therapeutics reported a net loss of $90.8 million, or $0.81 per share, for the third quarter ended September 30, 2025, an increase from a net loss of $24.9 million, or $0.22 per share, in Q3 2024, primarily due to a rise in research and development expenses to $90.0 million from $22.8 million.
The company maintained a strong quarter-end cash position of $715 million in cash, cash equivalents, and short-term investments as of September 30, 2025.
Significant progress was made with the VK2735 obesity program, with Phase 3 VANQUISH trials for subcutaneous VK2735 proceeding on schedule and positive top-line results from the Phase 2 VENTURE-Oral Dosing study demonstrating up to 12.2% mean weight loss after 13 weeks.
Viking plans to file an Investigational New Drug (IND) application for its amylin agonist program in the first quarter of 2026.

Oct 22, 2025, 8:10 PM

8-K

Viking Therapeutics Reports Q3 2025 Financial Results and Clinical Pipeline Updates

VKTX

Earnings

New Projects/Investments

Viking Therapeutics reported a net loss of $90.8 million, or $0.81 per share, for the third quarter ended September 30, 2025.
The company maintained a strong quarter-end cash position of $715 million as of September 30, 2025.
Phase 3 VANQUISH trials for subcutaneous VK2735 in obesity are proceeding on schedule, with enrollment for VANQUISH-1 expected to complete by the end of 2025 and VANQUISH-2 in the first quarter of 2026.
The Phase 2 VENTURE-Oral Dosing study of VK2735 successfully achieved its primary and secondary endpoints, demonstrating statistically significant reductions in body weight of up to 12.2% from baseline after 13 weeks.
Viking plans to file an Investigational New Drug (IND) application for its dual amylin and calcitonin receptor agonist (DACRA) program in the first quarter of 2026.

Oct 22, 2025, 8:05 PM

Press Release

Viking Therapeutics Updates on Obesity Pipeline and Financial Position

VKTX

New Projects/Investments

Viking Therapeutics' lead program, VK2735, a dual GLP-1 and GIP receptor agonist for obesity, has its subcutaneous formulation in Phase 3 trials (Vanquish program).
The oral formulation of VK2735 recently completed a successful Phase 2 study, demonstrating up to 12% reduction in body weight after 13 weeks and a promising tolerability profile.
The company plans an end-of-phase 2 FDA meeting in Q4 to determine the path forward for the oral formulation.
Viking Therapeutics ended Q2 with over $800 million in cash, which is expected to fund the Phase 3 trials.

Sep 23, 2025, 3:20 PM

Transcript

Viking Therapeutics Provides Update on Obesity Pipeline and Financial Position

VKTX

New Projects/Investments

Guidance Update

Viking Therapeutics' lead program, VK2735, a dual GLP-1 and GIP receptor agonist, is in Phase 3 for obesity with its subcutaneous formulation, and its oral formulation recently completed a successful Phase 2 study, demonstrating up to 12% weight reduction after 13 weeks.
The company plans an end-of-phase 2 FDA meeting in Q4 2025 for the oral VK2735 and will initiate a subcutaneous-to-oral maintenance study late Q3 2025 or early Q4 2025.
Viking Therapeutics ended Q2 2025 with over $800 million in cash, providing the financial runway to complete its Phase 3 trials.
The company is also advancing an amylin agonist program, with plans to move it into the clinic late 2025 or early 2026, aiming to potentially offer enhanced weight loss efficacy.

Sep 23, 2025, 3:20 PM

Transcript

Filings & Transcripts

View All Documents

Recent SEC filings and earnings call transcripts for VKTX.

No recent filings or transcripts found for VKTX.